Evaluation of collagen/heparin coated TCP/HA granules for long-term delivery of BMP-2

Journal of Materials Science: Materials in Medicine

Volumn 24, Issue 2, 2013, Pages 325-332

  Hannink, Gerjon ^a   Geutjes, Paul J ^a   Daamen, Willeke F ^a   Buma, Pieter ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING AND RELEASE; BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; BONE SUBSTITUTES; COLLAGEN TYPE I; DELIVERY SYSTEMS; OSTEOINDUCTIVE EFFECTS; RELEASE PATTERN;

BONE; COLLAGEN; HYDROGELS; POLYSACCHARIDES;

GRANULATION;

COLLAGEN TYPE 1; HEPARIN; HYDROXYAPATITE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2;

ANIMAL TISSUE; ARTICLE; BONE PROSTHESIS; BONE REGENERATION; CLINICAL EVALUATION; DRUG DELIVERY SYSTEM; HUMAN; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; BONE SUBSTITUTES; CALCIUM PHOSPHATES; CHO CELLS; COATED MATERIALS, BIOCOMPATIBLE; COLLAGEN; CRICETINAE; CRICETULUS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DURAPATITE; HEPARIN; NANOPARTICLES;

EID: 84878355765     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-012-4802-4     Document Type: Article

References (38)

1. Giannoudis PV. Chris Arts JJ, Schmidmaier G, et al. What should be the characteristics of the ideal bone graft substitute? Injury. 2011;42(Suppl 2):S1-2.
2. Larsson S, Hannink G. Injectable bone-graft substitutes: current products, their characteristics and indications, and new developments. Injury. 2011;42(Suppl 2):S30-4.
3. LeGeros RZ. Properties of osteoconductive biomaterials: calcium phosphates. Clin Orthop Relat Res. 2002;395(395):81-98.
4. LeGeros RZ, Lin S, Rohanizadeh R, et al. Biphasic calcium phosphate bioceramics: preparation, properties and applications. J Mater Sci Mater Med. 2003;14(3):201-9.
5. Hannink G, Arts JJ. Bioresorbability, porosity and mechanical strength of bone substitutes: what is optimal for bone regeneration? Injury. 2011;42(Suppl 2):S22-5.
6. Takahashi Y, Yamamoto M, Tabata Y. Enhanced osteoinduction by controlled release of bone morphogenetic protein-2 from biodegradable sponge composed of gelatin and beta-tricalcium phosphate. Biomaterials. 2005;26(23):4856-65.
7. Helm GA, Sheehan JM, Sheehan JP, et al. Utilization of type I collagen gel, demineralized bone matrix, and bone morphogenetic protein-2 to enhance autologous bone lumbar spinal fusion. J Neurosurg. 1997;86(1):93-100.
8. Yang XB, Whitaker MJ, Sebald W, et al. Human osteoprogenitor bone formation using encapsulated bone morphogenetic protein 2 in porous polymer scaffolds. Tissue Eng. 2004;10(7-8):1037-45.
9. Arnander C, Westermark A, Veltheim R, et al. Three-dimensional technology and bone morphogenetic protein in frontal bone reconstruction. J Craniofac Surg. 2006;17(2):275-9.
10. Noshi T, Yoshikawa T, Ikeuchi M, et al. Enhancement of the in vivo osteogenic potential of marrow/hydroxyapatite composites by bovine bone morphogenetic protein. J Biomed Mater Res. 2000;52(4):621-30.
11. Jeon O, Song SJ, Kang SW, et al. Enhancement of ectopic bone formation by bone morphogenetic protein-2 released from a heparin-conjugated poly(L-lactic-co-glycolic acid) scaffold. Biomaterials. 2007;28(17):2763-71.
12. Haidar ZS, Hamdy RC, Tabrizian M. Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part A: current challenges in BMP delivery. Biotechnol Lett. 2009;31(12):1817-24.
13. Haidar ZS, Hamdy RC, Tabrizian M. Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part B: delivery systems for BMPs in orthopaedic and craniofacial tissue engineering. Biotechnol Lett. 2009;31(12):1825-35.
14. Rose FR, Hou Q, Oreffo RO. Delivery systems for bone growth factors - the new players in skeletal regeneration. J Pharm Pharmacol. 2004;56(4):415-27.
15. Nillesen ST, Geutjes PJ, Wismans R, et al. Increased angiogenesis and blood vessel maturation in acellular collagen-heparin scaffolds containing both FGF2 and VEGF. Biomaterials. 2007;28(6):1123-31.
16. Wissink MJ, Beernink R, Pieper JS, et al. Binding and release of basic fibroblast growth factor from heparinized collagen matrices. Biomaterials. 2001;22(16):2291-9.
17. Ruppert R, Hoffmann E, Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem. 1996;237(1):295-302.
18. Pieper JS, Hafmans T, van Wachem PB, et al. Loading of collagen-heparan sulfate matrices with bFGF promotes angiogenesis and tissue generation in rats. J Biomed Mater Res. 2002;62(2):185-94.
19. Sommer A, Rifkin DB. Interaction of heparin with human basic fibroblast growth factor: protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan. J Cell Physiol. 1989;138(1):215-20.
20. Gospodarowicz D, Cheng J. Heparin protects basic and acidic FGF from inactivation. J Cell Physiol. 1986;128(3):475-84.
21. Zhao B, Katagiri T, Toyoda H, et al. Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2. J Biol Chem. 2006;281(32):23246-53.
22. Jackson RA, McDonald MM, Nurcombe V, et al. The use of heparan sulfate to augment fracture repair in a rat fracture model. J Orthop Res. 2006;24(4):636-44.
23. Blanquaert F, Saffar JL, Colombier ML, et al. Heparan-like molecules induce the repair of skull defects. Bone. 1995;17(6):499-506.
24. Pieper JS, Oosterhof A, Dijkstra PJ, et al. Preparation and characterization of porous crosslinked collagenous matrices containing bioavailable chondroitin sulphate. Biomaterials. 1999;20(9):847-58.
25. Pieper JS, Hafmans T, Veerkamp JH, et al. Development of tailor-made collagen-glycosaminoglycan matrices: EDC/NHS crosslinking, and ultrastructural aspects. Biomaterials. 2000;21(6):581-93.
26. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(5259):680-5.
27. Jeon O, Ryu SH, Chung JH, et al. Control of basic fibroblast growth factor release from fibrin gel with heparin and concentrations of fibrinogen and thrombin. J Control Release. 2005;105(3):249-59.
28. Liu LS, Ng CK, Thompson AY, et al. Hyaluronate-heparin conjugate gels for the delivery of basic fibroblast growth factor (FGF-2). J Biomed Mater Res. 2002;62(1):128-35.
29. Perets A, Baruch Y, Weisbuch F, et al. Enhancing the vascularization of three-dimensional porous alginate scaffolds by incorporating controlled release basic fibroblast growth factor microspheres. J Biomed Mater Res A. 2003;65(4):489-97.
30. King GN. The importance of drug delivery to optimize the effects of bone morphogenetic proteins during periodontal regeneration. Curr Pharm Biotechnol. 2001;2(2):131-42.
31. den Boer FC, Wippermann BW, Blokhuis TJ, et al. Healing of segmental bone defects with granular porous hydroxyapatite augmented with recombinant human osteogenic protein-1 or autologous bone marrow. J Orthop Res. 2003;21(3):521-8.
32. Winn SR, Uludag H, Hollinger JO. Carrier systems for bone morphogenetic proteins. Clin Orthop Relat Res Suppl. 1999;367(367 Suppl):95-106.
33. Alam MI, Asahina I, Ohmamiuda K, et al. Evaluation of ceramics composed of different hydroxyapatite to tricalcium phosphate ratios as carriers for rhBMP-2. Biomaterials. 2001;22(12):1643-51.
34. Arts JJ, Gardeniers JW, Welten ML, et al. No negative effects of bone impaction grafting with bone and ceramic mixtures. Clin Orthop. 2005;438:239-47.
35. Chow LC. Next generation calcium phosphate-based biomaterials. Dent Mater J. 2009;28(1):1-10.
36. Brodie JC, Goldie E, Connel G, et al. Osteoblast interactions with calcium phosphate ceramics modified by coating with type I collagen. J Biomed Mater Res A. 2005;73(4):409-21.
37. Weadock K, Olson RM, Silver FH. Evaluation of collagen crosslinking techniques. Biomater Med Devices Artif Organs. 1983;11(4):293-318.
38. Takada T, Katagiri T, Ifuku M, et al. Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins. J Biol Chem. 2003;278(44):43229-35.